Adienne Pharma & Biotech has signed an agreement for the manufacture of Russia’s Sputnik V COVID-19 vaccine. This paves the way for Italy to become the first European Union nation to manufacture the Sputnik V vaccine.
The first European Union Sputnik V manufacturing agreement
In a statement released on Monday, the Italian-Russian Chamber of Commerce (CCIR), announced that Adienne Pharma & Biotech SA has entered into a manufacturing agreement with the Russia Direct Investment Fund (RDIF), which funds the production and distribution of Sputnik V.
Under the agreement, Italian-Swiss Adienne is to manufacture the Sputnik V vaccine near Milan, in Italy’s Lombardy region. This is the first-ever European manufacturing agreement for the Russian vaccine.
Production in Italy may start in July 2021
Although the Sputnik V vaccine is still being assessed by the European Medicines Agency (EMA), production of the vaccine could start as early as July. The Sputnik V vaccine has already been ordered and administered in some EU countries including Hungary and Slovakia, without waiting for the EU regulator.
The heterologous recombinant adenovirus vaccine, which has been met with some skepticism in the West is now approved in 46 countries around the world including Argentina, Mexico, Egypt, Ghana, Iran, and the UAE. Sputnik V became the first registered vaccine against SARS-CoV-2 during August 2020.
Sputnik V vaccine is up to 91.6% effective
According to the medical journal, the Lancet, the Sputnik V vaccine is up to 91.6% effective against symptomatic forms of the COVID-19 disease. It is a two-dose jab, administered 21-days apart as an injection into the deltoid muscle.
Developed by the Russian government-backed Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V, also known as Gam-COVID-Vac, is a viral two-vector vaccine based on two human adenoviruses (types 26 and 5) containing the gene that encodes the full-length spike protein (S) of SARS-CoV-2 to stimulate an immune response.